Fosaprepitant 150 mg/5mL (Fosaprepitant Dimeglumine INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 150 mg/5mL

Fosaprepitant 150 mg/5mL is a lyophilized powder for solution, used for managing chemotherapy-induced nausea and vomiting. This intravenous injection is designed for single-dose administration.

Strength

150 mg/5mL

Pack Size

1 VIAL, SINGLE-DOSE in 1 CARTON (0338-0008-01) / 5 mL in 1 VIAL, SINGLE-DOSE

Manufacturer / TM Owner

Baxter Healthcare Corporation

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Fosaprepitant is primarily used to prevent nausea and vomiting caused by chemotherapy. It belongs to a class of medications known as substance P/neurokinin 1 (NK1) receptor antagonists. This medication is often administered before chemotherapy to help manage these side effects. Fosaprepitant works by blocking neurotransmitters in the brain that trigger nausea and vomiting.

Side Effects

Common effects of Fosaprepitant may include fatigue, headache, and diarrhea. Some individuals might experience infusion-related reactions such as flushing or rash. These effects are generally mild and temporary. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Fosaprepitant should be used with caution in patients with a history of severe allergic reactions to similar medications. It is important to inform your healthcare provider about any other medications you are taking to avoid potential interactions. Follow the prescribed dosage and administration instructions carefully.

Avoid Interactions

Fosaprepitant may interact with other medications, including those metabolized by the liver's cytochrome P450 system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Avoid consuming alcohol while using Fosaprepitant, as it may increase the risk of side effects.

References

Frequently Asked Questions

Fosaprepitant is used to prevent nausea and vomiting caused by chemotherapy.

Fosaprepitant is administered intravenously as a single-dose injection.

Common side effects may include fatigue, headache, and diarrhea.

Fosaprepitant may interact with other medications, so it is important to consult a healthcare provider.

Fosaprepitant should be used with caution in patients with a history of severe allergic reactions.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.